Egypt has an ongoing long history with beekeeping, which started with the ancient Egyptians making various reliefs and inscriptions of beekeeping on their tombs and temples. The Egyptian honeybee (Apis mellifera lamarckii) is an authentic Egyptian honeybee subspecies utilized in apiculture. A. m. lamarckii is a distinct honeybee subspecies that has a particular body color, size, and high levels of hygienic behavior. Additionally, it has distinctive characteristics; including the presence of the half-queens, an excessive number of swarm cells, high adaptability to climatic conditions, good resistance to specific bee diseases, including the Varro disorder, and continuous breeding during the whole year despite low productivity, using very little propolis, and tending to abscond readily. This review discusses the history of beekeeping in Egypt and its current situation in addition to its morphology, genetic analysis, and distinctive characters, and the defensive behaviors of native A. m. lamarckii subspecies.

Background/Objectives: This study evaluated the therapeutic efficacy of folic acid-functionalized chitosan-coated oleosomes (F-CS-OL) loaded with Syzygium cumini (SYG) seed extract against rheumatoid arthritis (RA) in a complete Freund’s adjuvant (CFA)-induced arthritis rat model. Methods: Rats received treatments via the oral route for 11 days following arthritis induction. The colloidal formulation exhibited an average particle size of 80.78 ± 1.02 nm, a zeta potential of −15.5 ± 1.12 mV, and an encapsulation efficiency (EE) of 94.98 ± 0.56%, alongside characterization by TEM, FTIR, and DSC. CFA-induced arthritis produced a pronounced inflammatory and angiogenic response, marked by significantly elevated serum levels of TNF-α, IL-6, CRP, VEGF, ICAM-1, MMP-3, and CXCL13 compared with the normal control group. Results: While treatment with free SYG extract resulted in moderate reductions in these biomarkers, the nanoencapsulated extract (SYG-loaded F-CS-OL) produced significantly greater reductions in inflammatory, chemotactic, matrix-remodeling, and angiogenesis-associated biomarkers compared with the untreated CFA-induced arthritis group. Histopathological examination of joint tissues further supported the biochemical findings. Conclusions: Overall, SYG-loaded F-CS-OL exhibited potent anti-inflammatory, immunomodulatory activities and significantly reduced biomarkers associated with angiogenic signaling in CFA-induced arthritis in CFA-induced arthritis. These findings suggest that folic acid-functionalized nanocarriers may represent a promising strategy for enhancing the therapeutic potential of SYG; however, further pharmacokinetic and safety studies are warranted to support clinical translation.